Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — H1 2020 Earnings Presentation

39 slides from Aspen Pharmacare's earnings presentation, Mar 6, 2020

  1. Slide 1: 2020 Interim Results Presentation

    2020 INTERIM RESULTS PRESENTATION For the six months ended 31 December 2019

  2. Slide 2: Disclaimer

    DISCLAIMER CAUTIONARY REGARDING FORWARD-LOOKING STATEMENTS We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward looking statements as defined in the U.S.

  3. Slide 3: Disclosure Note

    DISCLOSURE NOTE • Results separately disclose discontinued operations arising from the completed disposals of the Nutritionals business, Non-core pharmaceutical portfolio in the Asia Pacific region, Japanese business and Public sector ARVs. • Adoption of new IFRS 16 Leases  Retrospectively applied

  4. Slide 4: Financial Review

    FINANCIAL REVIEW

  5. Slide 5: Financial Summary

    FINANCIAL SUMMARY CONTINUING % Change vs PY R’million H1 2020 Reported CER * Net revenue 18 417 3% 3% Gross profit 9 410 -3% -3% Gross profit margin 51.1% 54.1% 54.0% Normalised EBITDA 5 260 0% 0% Normalised EBITDA margin 28.6% 29.3% 29.3% Normalised tax (610) 5% 4% Normalised effective tax rate 15.

  6. Slide 6: Segmental (CER)

    SEGMENTAL (CER) CONTINUING Regional Brands Sterile Focus Brands H1 2020 4628 8284 H1 2020 3940 6962 H1 2019 (CER) 4627 7834 H1 2019 (CER) 3975 7120 • Regional Brands show revenue growth • Improved gross profit percentage from Sterile Focus, notwithstanding declines in the oncology portfolio despite

  7. Slide 7: Gross Margin Percentage (CER)

    GROSS MARGIN PERCENTAGE (CER) CONTINUING Group Regional Brands 54.0% 59.1% 52.2% 57.8% 51.1% 56.5% 50.3% 55.9% H1 2019 H2 2019 FY 2019 H1 2020 H1 2019 H2 2019 FY 2019 H1 2020 Sterile Focus Brands Manufacturing 59.9% 36.2% 55.8% 56.5% 56.6% 26.3% 26.6% 16.0% H1 2019 H2 2019 FY 2019 H1 2020 H1 2019 H2

  8. Slide 8: Normalised EBITDA

    NORMALISED EBITDA CONTINUING R'million H1 2020 % of revenue H1 2019 (CER) * % of revenue % change Gross profit ** 9 410 51.1% 9 683 54.0% -2.8% Operating expenses (4 821) -26.2% (4 801) -26.8% 0.4% Net other operating income 220 1.2% 15 0.1% >100% Depreciation 451 2.5% 363 2.0% 24.4% Normalised EBIT

  9. Slide 9: Currency Impact

    CURRENCY IMPACT CONTINUING Contribution to Contribution to Average FX Rates to ZAR H1 2020 FY 2019 H1 2019 revenue Normalised EBITDA EUR 31% 18% 16.30 16.19 16.34 AUD 11% 20% 10.05 10.15 10.27 CNY 9% 20% 2.09 2.08 2.07 USD 6% -22% 14.69 14.19 14.19 • Low year on year volatility in currency • ZAR con

  10. Slide 10: Effective Tax Rates

    EFFECTIVE TAX RATES CONTINUING 30% 28.6% • The Group’s effective tax rate spiked in FY 2019 due to higher impairments in that year 25% • Normalised effective tax rate eliminates the periodic spikes and other 18.1% 20% non-trading items 16.6% 17.0% • Normalised effective tax rate in H1 2020 is 0,5% g

  11. Slide 11: Reconciliation of CER NHEPS

    RECONCILIATION OF CER NHEPS CONTINUING Cents H1 2020 H1 2019 (CER) * % change Basic earnings per share (EPS) 533.0 594.2 -10% Profit on sale of property, plant and equipment 1.1 0.1 >100% Impairment of property, plant and equipment 1.7 1.5 13% Impairment of intangible assets 107.1 45.8 >100% Reversa

  12. Slide 12: NHEPS Bridge (CER)

    NHEPS BRIDGE (CER) CONTINUING R’MILLION 3 226 3 227 -28 -72 142 -40 South Africa - ZAR 23% International - EUR 69% Normalised HEPS (CER) Normalised EBITDA Depreciation Amortisation Finance costs Normalised HEPS (Reported) - 31 December 2018 - 31 December 2019 CER reflects the underlying operational

  13. Slide 13: Working Capital

    WORKING CAPITAL CONTINUING R’million H1 2020 H1 2019 (CER) * FY 2019 (CER) * Net Working capital - comparable base 17 174 18 229 16 440 Net Working capital - excluding Oss 12 255 13 282 11 727 Working capital % of revenue 47% 51% 46% Less: Attributable to Oss -9% -9% -9% Working capital excluding Os

  14. Slide 14: Capital Expenditure

    CAPITAL EXPENDITURE PPE CAPEX IN R’MILLION 2 600 2 442 H2 2020 2 145 1 588 1 500 H2 2019 1 800 1 200 H1 2020 1 012 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 • Expected first commercial production from strategic projects  Port Elizabeth FY 2021 Actual Planned  Bad Oldesloe FY 2021 • Planned capex is

  15. Slide 15: Borrowings

    BORROWINGS ANALYSIS OF NET BORROWINGS R'million unless stated otherwise H1 2020 pro-forma # H1 2020 H1 2019 Net normalised funding costs ^ ( 688) ( 688) ( 853) Gearing (%) 37% 40% 51% Net Debt/EBITDA (x) * 3,3x 3.5x 4.4x Interest cover ratio (x) * 5.1x 5.3x 5.4x ** Effective interest rate for the pe

  16. Slide 16: Net Borrowings Bridge

    NET BORROWINGS BRIDGE R’MILLION Operations related R1 298 million 38 984 39 013 274 -609 638 37 989 -2 595 5 1 292 South Africa - ZAR 23% International - EUR 69% Net borrowings as FX impact IFRS 16 Net borrowings Transaction related Cashflows from Capex (IP and PPE) Other Net Borrowings at at 30 Jun

  17. Slide 17: Key Cash Flow Commitment Trends

    KEY CASH FLOW COMMITMENT TRENDS R'million FY 2018 FY 2019 H1 2020 H2 2020 FY 2020 Future trend / Comments Declining sharply after FY 2020 and then stabalising - refer to Capital expenditure - PPE 2 145 2 442 1 012 1 588 2 600 slide 14 Capital expenditure - Intangible 6 083 1 522 280 541 821 Opportun

  18. Slide 18: Group Strategy and Performance Review

    GROUP STRATEGY AND PERFORMANCE REVIEW

  19. Slide 19: Significant Progress on Our Medium-Term Priorities

    SIGNIFICANT PROGRESS ON OUR MEDIUM-TERM PRIORITIES • Increase focus  Focus on our pharmaceutical businesses and continuing to build on areas of competitive advantage  Seeking partnering opportunities in markets where we are sub-scale • Build on our strengths  Continue development of our complex m

  20. Slide 20: Group Revenue

    GROUP REVENUE CONTINUING Developed markets Emerging markets R’million H1 2020 H1 2019 % change H1 2019 (CER) * % change -1% CER growth +4% CER growth Commercial Pharma 15 246 14 892 2% 14 953 2% R6.1bn 40% Regional Brands 8 284 7 812 6% 7 833 6% R9.1bn Sterile Focus Brands 6 962 7 080 -2% 7 120 -2%

  21. Slide 21: Group Revenue – By Region

    GROUP REVENUE – BY REGION CONTINUING – Focused effort in delivering organic growth and controlling costs Europe CIS Aspen regions R'million H1 2020 H1 2019 (CER)* % change -6% CER growth (excluding Europe CIS) +6% CER growth Commercial Pharma 15 246 14 953 2% Europe CIS Asia Pacific 4 320 4 086 6% 3

  22. Slide 22: Commercial Pharma – Aspen Regions, Excluding Europe CIS

    COMMERCIAL PHARMA – ASPEN REGIONS, EXCLUDING EUROPE CIS CONTINUING – Improving performance R'million H1 2020 H1 2019 (CER)* % change Regional Brands 7 186 6 792 6% Asia Pacific 1 996 1 919 4% Africa & Middle East ƚ 3 866 3 667 5% Americas ^ 1 324 1 206 10% Sterile Focus brands 3 294 3 097 6% Asia Pa

  23. Slide 23: Commercial Pharma - Europe CIS

    COMMERCIAL PHARMA - EUROPE CIS CONTINUING – Commercial intervention underway R'million H1 2020 H1 2019 (CER)* % change Regional Brands 1 099 1 041 6% Sterile Focus Brands 3 668 4 023 -9% Thrombosis 2 462 2 740 -10% Anaesthetics 1 206 1 283 -6% Total 4 767 5 064 -6% • Sterile Focus Brands impacting E

  24. Slide 24: Commercial Pharma – Europe CIS – Sterile Focus Brands

    COMMERCIAL PHARMA – EUROPE CIS – STERILE FOCUS BRANDS CONTINUING – Commercial intervention and supply impacting positively, sustainable performance required >20% >20% Q1 Q2 Q1 Q2 Anaesthetics Europe CIS quarterly sales for H1 2020 (reported), in EUR’m Thrombosis Europe CIS quarterly sales for H1 202

  25. Slide 25: Manufacturing – API & FDF

    MANUFACTURING – API & FDF CONTINUING – Delivering efficiencies R’million H1 2020 H1 2019 (CER) * % change FDF 20% API 2 543 2 290 11% FDF 628 694 -10% API 80% Total 3 171 2 984 6% • API +11%  Driven by heparin sales to third parties in H1 2020 Manufacturing R3.2bn  Benefit of heparin stockpile  L

  26. Slide 26: Outcome from the Group Strategic Review

    OUTCOME FROM THE GROUP STRATEGIC REVIEW SA – Aspen and Ethicare Partnership across public sector ARVs • Heightened focus driving momentum across the two portfolios • Aspen maintains a social commitment towards our South African patients  Aspen – branded portfolio  Ethicare – commoditised/traded po

  27. Slide 27: Outcome from the Group Strategic Review

    OUTCOME FROM THE GROUP STRATEGIC REVIEW Divestment of Japanese Business EU Strategic review • Aspen has performed in this market • Restructuring of Europe CIS is progressing  Faced unilateral price decreases annually  Some benefits already visible in Q2 performance  Critical to have a pipeline to

  28. Slide 28: Outlook – Based on Business as Usual (excluding COVID-19)

    OUTLOOK – BASED ON BUSINESS AS USUAL (excluding COVID-19) Potential for FY 2020 to outperform FY 2019 • Commercial Pharma revenue H2 > H1  Growth in Regional and Sterile Brands 31 Dec 2018 R53.5 bn -38% in Net debt  Impetus from SA and Latam to be maintained  Europe CIS H2 improvement R20.1 bn 

  29. Slide 29: Appendices

    Y Cu Y (a) za Lo al aa <

  30. Slide 30: Appendix 1: Abridged Statement of Comprehensive Income

    APPENDIX 1: ABRIDGED STATEMENT OF COMPREHENSIVE INCOME CONTINUING AND DISCONTINUED R’million H1 2020 H1 2019 % change Net revenue 19 993 21 597 -7% Cost of sales (9 887) (10 460) Gross profit 10 106 11 137 -9% Gross profit margin 50.5% 51.6% Operating expenses (5 144) (5 612) Net other operating exp

  31. Slide 31: Appendix 2: Abridged Statement of Normalised Comprehensive Income

    APPENDIX 2: ABRIDGED STATEMENT OF NORMALISED COMPREHENSIVE INCOME CONTINUING R’million H1 2020 H1 2019 % change H1 2019 (CER)* % change Net revenue 18 417 17 878 3% 17 937 3% Cost of sales (9 007) (8 209) 10% (8 255) Gross profit 9 410 9 669 -3% 9 682 -3% Gross profit margin 51.1% 54.1% 54.0% Operat

  32. Slide 32: Appendix 3: Reconciliation of Reported NHEPS

    APPENDIX 3: RECONCILIATION OF REPORTED NHEPS CONTINUING AND DISCONTINUED Cents H1 2020 H1 2019 % change Basic earnings per share (EPS) 576.0 643.4 -10% Impairment of property, plant and equipment 1.5 1.5 1% Impairment of intangible assets 106.6 46.0 >100% Loss on sale of discontinued operations 8.7

  33. Slide 33: Appendix 4: Group Statement of Financial Position

    APPENDIX 4: GROUP STATEMENT OF FINANCIAL POSITION CONTINUING R'million H1 2020 H1 2019 FY 2019 R‘million H1 2020 H1 2019 FY 2019 TOTAL ASSETS EQUITY AND LIABILIITIES Non-current assets 79 745 89 475 86 164 Shareholders equity 55 962 52 290 54 213 Intangible assets 60 153 70 297 66 468 Non-current li

  34. Slide 34: Appendix 5: Extract from Group Statement of Cash Flows

    APPENDIX 5: EXTRACT FROM GROUP STATEMENT OF CASH FLOWS CONTINUING AND DISCONTINUED R'million H1 2020 H1 2019 % change Cash operating profit 5 577 5 852 -5% Changes in working capital (1 217) (2 253) Cash generated from operations 4 360 3 599 21% Net finance costs paid ( 889) ( 765) Tax paid ( 876) (

  35. Slide 35: Appendix 6: Net Funding Costs

    APPENDIX 6: NET FUNDING COSTS CONTINUING Cumulative change in margin applicable to the Group's R’million H1 2020 H1 2019 syndicated term and revolving loans for changes in Net interest paid ( 591) ( 639) leverage ratio: Foreign exchange (losses)/gains ( 10) ( 40) >4,50x but <4,75x +0,750% Notional i

  36. Slide 36: Appendix 7: Group Revenue by Region

    APPENDIX 7: GROUP REVENUE BY REGION CONTINUING R’million H1 2020 H1 2019* % Change H1 2019 (CER)** % Change Developed Europe 6 261 6 210 1% 6 200 1% Sub-Saharan Africa 3 904 3 635 7% 3 642 7% Asia Pacific 4 543 4 357 4% 4 353 4% Latin America 1 694 1 551 9% 1 566 8% Developing Europe and CIS 1 157 1

  37. Slide 37: Appendix 8: Commercial Pharma Revenue Segment

    APPENDIX 8: COMMERCIAL PHARMA REVENUE SEGMENT CONTINUING – PREVIOUS DISCLOSURE R’million H1 2020 H1 2019* % change H1 2019 (CER)** % change Regional Brands 8 284 7 811 6% 7 834 6% Regional Brands 6 346 5 955 7% 5 953 7% High Potency & Cytotoxics 1 938 1 856 4% 1 881 3% Sterile Focus Brands 6 962 7 0

  38. Slide 38: Appendix 9: IFRS Restatements

    APPENDIX 9: IFRS RESTATEMENTS IAS 17 IFRS 16 • Adoption of new IFRS 16 Leases Statement of comprehensive income  Retrospectively applied from 1 July 2019, Operating lease expense 86 - using a modified retrospective approach Interest paid-leases - 16  Comparatives are not restated under this Deprec

  39. Slide 39: Appendix 10: Portfolio Management Model

    APPENDIX 10: PORTFOLIO MANAGEMENT MODEL Maximise portfolio Build portfolio Reshape portfolio returns Drivers of portfolio Aspen Portfolio strategy Sales & Supply Acquire Develop Collaborate Manufacturing Revitalise Collaborate Divest Marketing Chain Patients Needs Proactively seek Leverage Strategic

Aspen Pharmacare Holdings — H1 2020 Earnings Presentation on 6ix